Mkt Cap $12M
52-Week Range
SeaStar Medical Holding Corporation (ICU) reported FY 2025 net revenue of $1.23 million, a significant +814% YoY increase from $0.14 million in 2024, driven by initial commercialization of QUELIMMUNE pediatric SCD therapy following FDA HDE approval in February 2024, with first shipments in July 2024.
$12M
Market Cap
$930.8K
Revenue
-$14M
Net Income
SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.